Literature DB >> 11162860

Expression of cyclin E and cyclin D1 in non-small cell lung cancers.

H Yamanouchi1, M Furihata, J Fujita, H Murakami, T Yoshinouchi, J Takahara, Y Ohtsuki.   

Abstract

The relationships between overexpression of cyclin D1 or cyclin E and clinicopathological factors were investigated in 157 patients with non-small cell lung cancers (NSCLCs) using immunohistochemical analysis. Fifty-eight cases of NSCLCs (58/157, 37%) showed the overexpression of cyclin D1, and 64 cases (64/157, 41%) were positive for cyclin E. Cyclin E and cyclin D1 were infrequently concurrently overexpressed (17/157, 10.8%). Overexpression of cyclin E was more frequently observed in squamous cell carcinoma (29/57, 51%) compared with that in adenocarcinoma (28/86, 33%) (P<0.05). In addition, overexpression of cyclin E was more frequently observed in poorly or moderately differentiated NSCLCs (52/103, 50%) than in well-differentiated ones (12/54, 22%) regardless of their histological types (P<0.01). On the contrary, there was no statistically significant relationship between cyclin D1 overexpression and histological types or grade of tumor differentiation. These findings suggest that expression of cyclin E was frequently independent of that of cyclin D1 and played some roles in the grade of tumor differentiation in NSCLCs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162860     DOI: 10.1016/s0169-5002(00)00160-4

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  6 in total

1.  Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss.

Authors:  Mary Tsikitis; Zhikai Zhang; Winfried Edelman; David Zagzag; Ganjam V Kalpana
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-12       Impact factor: 11.205

2.  Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer.

Authors:  Yan-Shen Shan; Hui-Ping Hsu; Ming-Derg Lai; Yu-Hsuan Hung; Chih-Yang Wang; Meng-Chi Yen; Yi-Ling Chen
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

3.  Cyclin D1 as a therapeutic target of renal cell carcinoma- a combined transcriptomics, tissue microarray and molecular docking study from the Kingdom of Saudi Arabia.

Authors:  Sajjad Karim; Jaudah A Al-Maghrabi; Hasan M A Farsi; Ahmad J Al-Sayyad; Hans-Juergen Schulten; Abdelbaset Buhmeida; Zeenat Mirza; Alaa A Al-Boogmi; Fai T Ashgan; Manal M Shabaad; Hend F NourEldin; Khalid B M Al-Ghamdi; Adel Abuzenadah; Adeel G A Chaudhary; Mohammed H Al-Qahtani
Journal:  BMC Cancer       Date:  2016-09-30       Impact factor: 4.430

4.  Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients.

Authors:  Qing-Shui Wang; Feng Li; Zi-Qiang Liao; Ke Li; Xin-Liu Yang; You-Yu Lin; Yi-Lin Zhao; Shu-Yun Weng; Yun Xia; Yan Ye; Su-Huan Li; Chen-Yi Wang; Yao Lin
Journal:  Cancer Med       Date:  2019-06-10       Impact factor: 4.452

5.  Genetic polymorphisms in cyclin D1 are associated with risk of renal cell cancer in the Chinese population.

Authors:  Jianxin Xue; Zhiqiang Qin; Xiao Li; Jianzhong Zhang; Yuxiao Zheng; Weizhang Xu; Qiang Cao; Zengjun Wang
Journal:  Oncotarget       Date:  2017-09-08

6.  [Brucine inhibits the proliferation of human lung cancer cell line PC-9 
via arresting cell cycle].

Authors:  Miao Li; Ping Li; Mei Zhang; Feng Ma; Li Su
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.